IMPAACT Studies in Development

The study you are looking for is in protocol development.

As the study protocol reaches Version 1.0, a study page will be developed.

  Study Number
(DAIDS ID)
Study Title Status

IMPAACT 2017

(TBD)

Phase I/II Study of the Safety and Pharmacokinetics of Oral and Injectable Cabotegravir and Rilpivirine in Viriologically Suppressed HIV-Infected Adolescents

In Development

IMPAACT 2016

(TBD)

Evaluating a Group-Based Intervention to Improve Mental Health and ART Adherence in Adolescents Living with HIV in Low Resource Settings

In Development

IMPAACT 2014

(34150)

Phase I/II Study of the Pharmacokinetics, Safety and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-infected Children and Adolescents

In Development

IMPAACT 2015

(35123)

Evaluation of the HIV-1 Reservoir in the Central Nervous System of Perinatally-Infected Youth and Young Adults with a History of Neurocognitive Impairment

In Development

IMPAACT 2013

(30074)

Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, D46/NS2/N/delta M2-2-HindIII, Lot RSV#011B, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age

In Development

IMPAACT 2009

(30020)

Feasibility, Acceptability and Safety of Oral Pre-Exposure Prophylaxis for Primary HIV Prevention during Pregnancy and Breast Feeding in Adolescents and Young Women

In Development

IMPAACT 2003B

(12041)

(Phoenix) Protecting Households on Exposure to Newly Diagnosed Index Multidrug-Resistant TB Patients

In Development

IMPAACT 2006

(12069)

NextGen Strategy Trial: A Phase II, Randomized Study Assessing Lopinavir/Ritonavir- and Dolutegravir-Based Antiretroviral Treatment in Infants and Children >= 1 Month to < 3 Years of Age

In Development

IMPAACT 2005

(20721)

A Phase I/II Open-label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination with Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-infected and HIV-uninfected Children with MDR-TB

In Development


Return to the full list of studies

 

Funded by the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health of the US National Institutes of Health, US Department of Health and Human Services.